Clinical trials located in


Jette city is located in Belgium. Currently, 15 clinical trials are being conducted in this city.

Jette, located in the Brussels-Capital Region of Belgium, is a city that seamlessly blends historical charm with modern living. Known for its green spaces, Jette is home to the expansive King Baudouin Park, offering residents and visitors alike a tranquil escape from urban life. The city also boasts significant architectural heritage, including the Art Nouveau gems designed by architect René Magritte. Jette’s cultural landscape is enriched by the René Magritte Museum, located in the house where the famous surrealist painter lived and worked for 24 years, providing a deep dive into his life and art.

  • CT-EU-00117111

    Study assessing the effectiveness of Tebentafusp administered alone and in combination with Pembrolizumab in the treatment of advanced melanoma

    The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The main focus was on a new experimental drug called tebentafusp, which is a special type of protein that helps the body’s immune system recognize and attack cancer cells.

    The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient – this could be another experimental drug, standard therapy, or simply supportive care.

    Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses.

    AustriaBelgiumFranceGermanyItalyPolandSpainUnited Kingdom
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    BelgiumBulgariaDenmarkItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Testing new treatment for coagulation disorder

    The objective of this trial is to explore different methods of halting or reversing the blood-thinning effects of specific medications before an urgent surgery. The study compares two treatments: a new medicine named TAK-330 and a commonly used one called 4F-PCC. The goal is to determine which treatment is more effective. Participants in the study will be randomly assigned to receive either TAK-330 or 4F-PCC before their surgery, requiring a hospital stay. After the surgery, the research will assess how well the participants’ blood clotting functions during and after the procedure. The study will also monitor whether additional treatments were necessary to control bleeding. Any side effects or significant health changes will be tracked, and participants will be followed up for 30 days after the surgery to assess their recovery progress.

  • New approach to treating swelling in heart failure patients

    This innovative study focuses on improving treatment for patients with heart failure who are experiencing fluid overload. It involves using water pills (diuretics) in a novel way, guided by regularly checking the salt (sodium) levels in patients’ urine. By monitoring these levels, doctors can adjust the diuretic dosage more accurately, aiming to remove the right amount of excess fluid from the body. This tailored approach seeks to optimize the treatment process, alleviate symptoms like swelling and shortness of breath more effectively, and enhance the overall health and comfort of patients with acute heart failure. The study’s careful tracking and personalized treatment strategy promise to offer valuable insights into managing this challenging condition.

  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    BelgiumGermanyHungaryPolandUnited Kingdom
  • Tividenofusp Alfa vs Idursulfase: compare efficacy and safety in mucopolysaccharidosis type II

    This study aims to investigate a potential treatment for mucopolysaccharidosis type II (MPS II). The experimental drug, tividenofusp alfa (DNL310), will be compared to standard care-idursulfase. The goal is to assess the effectiveness and safety of this drug. Participants may have the option to enter an open-label treatment phase (a type of clinical trial in which both researchers and study participants are aware of the administered treatment), where participants will receive either DNL310 or idursulfase based on specific criteria.

    BelgiumCzechiaFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Testing Osilodrostat treatment in Cushing’s disease in children aged 6 years to 17 years

    This study involves investigating a drug called osilodrostat in young individuals with Cushing’s Disease. The primary focus is to observe how the drug behaves and moves within the body, its impact on the disease, and its safety. The trial spans approximately 12 weeks, beginning with a period of abstaining from other medications that could influence cortisol levels, a hormone that becomes elevated in individuals with Cushing’s Disease. If positive effects persist after 12 weeks, the testing period may extend for an additional 9 months to evaluate the long-term influence of the drug on the disease and its safety. The study aims to assess the drug’s efficacy by comparing urine cortisol levels at the start and end of the trial.

    BelgiumBulgariaItalySloveniaUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Testing new medication for advanced malignancies

    This study is about a new drug called INCA32459 in treating select advanced malignancies. The drug works by targeting two proteins, LAG-3 and PD-1, which are found in the body. The study has two parts. In the first part, different doses of the drug will be tested to see which one is most effective and safe. In the second part, the best dose identified in part 1 will be given to more patients. Researchers will continue to monitor the patients for side effects and will track how well the drug is working against the cancer.

  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalUnited Kingdom
  • Study on BOTOX for reducing jaw muscle prominence in adults

    This clinical trial explores the effectiveness of BOTOX (Botulinum Toxin Type A) injections in treating prominent jaw muscles, known as masseter muscle prominence (MMP), in adults. MMP causes a widened, square shape of the lower face, which some may find aesthetically displeasing. The study aims to find a non-surgical solution to achieve a narrower and more oval facial contour. Approximately 248 adults at various European locations will participate. They will be randomly assigned to receive either BOTOX or a placebo through six injections in the jaw muscle. The study includes follow-up treatments and assessments over six months to evaluate the treatment’s safety and effectiveness, including medical check-ups and questionnaires.

    BelgiumBulgariaFranceGermanyItalySpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.


See more clinical trials in other cities in Belgium: